Herpes simplex virus type 2 serological testing and psychosocial harm: A systematic review

Sexually Transmitted Infections

Volumn 87, Issue 7, 2011, Pages 594-600

  Ross, Kaile ^a   Johnston, Christine ^a,b   Wald, Anna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COLLEGE STUDENT; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; MENTAL HEALTH; NONHUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOSOCIAL DISORDER; SELF REPORT; SEROLOGY; SEXUAL BEHAVIOR;

ADOLESCENT; ADULT; AGED; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; SEROLOGIC TESTS; YOUNG ADULT;

EID: 82555164931     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sextrans-2011-050099     Document Type: Article

References (48)

1. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull WHO 2008;86:805-12A.
2. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296:964-73. (Pubitemid 44285373)
3. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52. (Pubitemid 34043015)
4. Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years - United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010;59:456-9.
5. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342:844-50. (Pubitemid 30165207)
6. Sacks SL, Griffiths PD, Corey L, et al. HSV-2 transmission. Antiviral Res 2004;63 (Suppl 1):S27-35. (Pubitemid 39140851)
7. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002;35(Suppl 2):S173-82. (Pubitemid 35178328)
8. Fairley I, Monteiro EF. Patient attitudes to type specific serological tests in the diagnosis of genital herpes. Genitourin Med 1997;73:259-62. (Pubitemid 27376687)
9. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis 2004;31:665-9. (Pubitemid 39426398)
10. Lowhagen GB, Berntsson M, Bonde E, et al. Acceptance and outcome of herpes simplex virus type 2 antibody testing in patients attending an STD clinic - recognized and unrecognized infections. Acta Derm Venereol 2005;85:248-52. (Pubitemid 40695170)
11. Mindel A, Taylor J. Debate: the argument against. Should every STD clinic patient be considered for type-specific serological screening for HSV? Herpes 2002;9:35-7. (Pubitemid 37486605)
12. Patrick DM, Money D. Debate: the argument for. Should every STD clinic patient be considered for type-specific serological screening for HSV? Herpes 2002;9:32-4. (Pubitemid 37486604)
13. Krantz I, Lowhagen GB, Ahlberg BM, et al. Ethics of screening for asymptomatic herpes virus type 2 infection. BMJ 2004;329:618-21. (Pubitemid 39256551)
14. Tarchini G. Asymptomatic herpes simplex virus type 2 shedding - potential pitfalls of broader testing and aggressive suppression. J Infect Dis 2010;202:979; author reply 979-80.
15. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59:1-110.
16. Glass N, Nelson H, Huffman L. Screening for Genital Herpes Simplex: Brief Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality, 2005.
17. Mark H, Gilbert L, Nanda J. Psychosocial well-being and quality of life among women newly diagnosed with genital herpes. J Obstet Gynecol Neonatal Nurs 2009;38:320-6.
18. Mindel A, Marks C. Psychological symptoms associated with genital herpes virus infections: epidemiology and approaches to management. CNS Drugs 2005;19:303-12. (Pubitemid 40593601)
19. Catotti DN, Clarke P, Catoe KE. Herpes revisited. Still a cause of concern. Sex Transm Dis 1993;20:77-80. (Pubitemid 23120833)
20. Wells G, Shea B, O'Connell D, et al. The Newcastle - Ottawa Scale (NOS) Assessing the Quality of Nonrandomized Studies in Meta-analyses. Canada: Department of Epidemiology and Community Medicine, University of Ottawa. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed 22 Jul 2011).
21. Bickford J, Barton SE, Mandalia S. Chronic genital herpes and disclosure. The influence of stigma. Int J STD AIDS 2007;18:589-92. (Pubitemid 351738913)
22. Crosby RA, Head S, DiClemente RJ, et al. Do protective behaviors follow the experience of testing positive for herpes simplex type 2? Sex Transm Dis 2008;35:787-90.
23. Crosby RA, Head S, Moore G, et al. Is suspicion of genital herpes infection associated with avoiding sex? A clinic-based study. Sex Health 2008;5:279-83.
24. Marchant J, Roe A. Genital herpes: recognizing and addressing patients' needs. Herpes 1997;4:36-41. (Pubitemid 27464576)
25. Mark H, Nanda JP, Joffe A, et al. Serologic screening for herpes simplex virus among university students: a pilot study. J Am Coll Health 2008;57:291-6.
26. Melville J, Sniffen S, Crosby R, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect 2003;79:280-5. (Pubitemid 37026343)
27. Meyer JL, Crosby RA, Whittington WL, et al. The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic. Sex Transm Infect 2005;81:309-15. (Pubitemid 41160735)
28. Miyai T, Turner KR, Kent CK, et al. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transm Dis 2004;31:517-21. (Pubitemid 39122132)
29. Narouz N, Allan PS, Wade AH, et al. Genital herpes serotesting: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UK. Sex Transm Infect 2003;79:35-41. (Pubitemid 36237825)
30. Richards J, Scholes D, Caka S, et al. HSV-2 serologic testing in an HMO population: uptake and psychosocial sequelae. Sex Transm Dis 2007;34:718-25. (Pubitemid 47312222)
31. Rosenthal SL, Zimet GD, Leichliter JS, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect 2006;82:154-7; discussion 157-8.
32. Smith A, Denham I, Keogh L, et al. Psychosocial impact of type-specific herpes simplex serological testing on asymptomatic sexual health clinic attendees. Int J STD AIDS 2000;11:15-20. (Pubitemid 30055131)
33. Wilkinson D, Barton S, Chard S, et al. The psychological consequences in patient undergoing a POCKit HSV-2 test. Int J STD AIDS 2000;11:551-2. (Pubitemid 30614399)
34. Youngkin EQ, Henry JK, Gracely-Kilgore K. Women with HSV and HPV: a strategy to increase self-esteem. Clin Excell Nurse Pract 1998;2:370-5.
35. Wild D, Patrick D, Johnson E, et al. Measuring health-related quality of life in persons with genital herpes. Qual Life Res 1995;4:532-9.
36. Provenzale A, Evans K, Russell J, et al. Psychosocial impact of a positive HSV-2 diagnosis on adults with unrecognized HSV-2 infection. Public Health Nurs 2011;28:325-34.
37. Burd ID, Nevadunsky N, Bachmann G. Impact of physician gender on sexual history taking in a multispecialty practice. J Sex Med 2006;3:194-200.
38. Tsimtsiou Z, Hatzimouratidis K, Nakopoulou E, et al. Predictors of physicians' involvement in addressing sexual health issues. J Sex Med 2006;3:583-8.
39. Anon. Taking shared decision making more seriously. Lancet 2011;377:784.
40. Dufrasne S, Roy M, Galvez M, et al. Experience over fifteen years with a protocol for predictive testing for Huntington disease. Mol Genet Metab 2011;102:494-504.
41. Duncan RE, Gillam L, Savulescu J, et al. "Holding your breath": interviews with young people who have undergone predictive genetic testing for Huntington disease. Am J Med Genet A 2007;143A:1984-9.
42. Christensen KD, Roberts JS, Uhlmann WR, et al. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 2011;13:409-14.
43. Green RC, Roberts JS, Cupples LA, et al. REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361:245-54.
44. Wilson J. To know or not to know? Genetic ignorance, autonomy and paternalism. Bioethics 2005;19:492-504. (Pubitemid 41527505)
45. Langenberg A, Benedetti J, Jenkins J, et al. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989;110:882-7. (Pubitemid 19153773)
46. Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006;194:42-52.
47. Corey L, Wald A, Patel R, et al. Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20. (Pubitemid 38032179)
48. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009;169:1233-40.